Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

Saito Sosei, Kana Yoshikawa, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Tsukasa Oikawa, PhD, Wenlin Du, MD, PhD, Taketo Yamada, MD, PhD, Maiko Matsushita, MD, PhD, Junya Seki, Kaoru Tohyama, MD, PhD, Yutaka Hattori, MD, PhD

Blood (2012) 120 (21): 1841.

https://doi.org/10.1182/blood.V120.21.1841.1841

Published: 2012

Journal Articles

A Novel Anilinoquinazoline Derivative Inhibits Growth of High-Risk Myeloma Cells In Vivo and Regulates Differentiation of Osteoclasts

Yoshie Ozaki, Yuhei Naito, Hiroshi Yanagawa, PhD, Yuya Suzuki, Wenlin Du, MD, PhD, Taketo Yamada, MD, PhD, Koichi Matsuo, MD, PhD, Nobuhide Doi, PhD, Shiro Iijima, PhD, Maiko Matsushita, MD, PhD, Kayoko Tahara, PhD, Yutaka Hattori, MD, PhD

Blood (2010) 116 (21): 4076.

https://doi.org/10.1182/blood.V116.21.4076.4076

Published: 2010

Journal Articles

Hepatocyte Growth Factor-Producing Multiple Myeloma (HGF myeloma) Is a Distinct Clinical Entity and Needs for Molecular Targeted Therapy.

Yutaka Hattori, Shin-ichiro Okamoto, MD, PhD, Wenlin Du, Taketo Yamada, Naoki Shimada, Kunio Matsumoto, Morihiko Sagawa, Yasuo Ikeda

Blood (2008) 112 (11): 1717.

https://doi.org/10.1182/blood.V112.11.1717.1717

Published: 2008

Journal Articles

NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor

Wenlin Du, Yutaka Hattori, Taketo Yamada, Kunio Matsumoto, Toshikazu Nakamura, Morihiko Sagawa, Takemi Otsuki, Takako Niikura, Toshihiro Nukiwa, Yasuo Ikeda

Blood (2006) 109 (7): 3042–3049.

https://doi.org/10.1182/blood-2006-02-003103

Published: 2006

Journal Articles

NK4, an Antagonist of Hepatocyte Growth Factor (HGF), Inhibits Growth of Multiple Myeloma Cells In Vitro and In Vivo : A Mouse Model for Molecular Targeting of Angiogenic Growth Factor.

Yutaka Hattori, MD, Wenlin Du, PhD, Taketo Yamada, MD, Kunio Matsumoto, PhD, Toshikazu Nakamura, MD, Takemi Otsuki, MD, Takako Niikura, PhD, Toshihiro Nukiwa, MD, Yasuo Ikeda, MD

Blood (2004) 104 (11): 637.

https://doi.org/10.1182/blood.V104.11.637.637

Published: 2004

NARROW

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

A Novel Anilinoquinazoline Derivative Inhibits Growth of High-Risk Myeloma Cells In Vivo and Regulates Differentiation of Osteoclasts

Hepatocyte Growth Factor-Producing Multiple Myeloma (HGF myeloma) Is a Distinct Clinical Entity and Needs for Molecular Targeted Therapy.

NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor

NK4, an Antagonist of Hepatocyte Growth Factor (HGF), Inhibits Growth of Multiple Myeloma Cells In Vitro and In Vivo : A Mouse Model for Molecular Targeting of Angiogenic Growth Factor.

Email alerts

ASH Publications

American Society of Hematology

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

A Novel Anilinoquinazoline Derivative Inhibits Growth of High-Risk Myeloma Cells In Vivo and Regulates Differentiation of Osteoclasts

Hepatocyte Growth Factor-Producing Multiple Myeloma (HGF myeloma) Is a Distinct Clinical Entity and Needs for Molecular Targeted Therapy.

NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor

NK4, an Antagonist of Hepatocyte Growth Factor (HGF), Inhibits Growth of Multiple Myeloma Cells In Vitro and In Vivo : A Mouse Model for Molecular Targeting of Angiogenic Growth Factor.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only